Lymphoma Posts
Dr. Lu discusses CD7-targeted CAR-T cell therapy at ASH 2024
Peihua Lu, MD, of Beijing Lu Daopei Institute of Hematology in China, stopped by the SOHO booth to speak with SOHO Insider during the 66th American Society of Hematology (ASH) […]
Tafasitamab plus lenalidomide, rituximab improves PFS in patients with relapsed or refractory follicular lymphoma
Addition of tafasitamab, a humanized CD19-targeting monoclonal antibody (mAb), to lenalidomide plus rituximab resulted in significant and clinically meaningful improvement in progression-free survival (PFS), representing a 57% reduction in risk of […]
CtDNA levels could serve as an early predictor of treatment success in LBCL
CtDNA is a valuable biomarker for monitoring disease burden and predicting durable clinical benefit in second-line large B-cell lymphoma (LBCL) treatment, according to data from the TRANSFORM trial. “CtDNA data […]
Researchers call for standardized reporting of toxicity outcomes in phase 1 lymphoma trials
Clearer standardized reporting of toxicity outcomes in phase 1 lymphoma trials is required for improved transparency and communication in drug development, according to a study published at the 66th American […]